Zealand Pharma A/S (OTCMKTS:ZLDPF) Upgraded to Strong-Buy at Zacks Research

Zacks Research upgraded shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) from a hold rating to a strong-buy rating in a report published on Monday morning,Zacks reports.

A number of other research analysts also recently weighed in on ZLDPF. Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. Jefferies Financial Group downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Berenberg Bank lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. Finally, Barclays lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold”.

Zealand Pharma A/S Stock Performance

ZLDPF stock opened at $34.87 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.98 and a quick ratio of 13.98. Zealand Pharma A/S has a 1 year low of $34.87 and a 1 year high of $83.12. The company has a market cap of $2.49 billion, a P/E ratio of 5.78 and a beta of 0.95. The stock’s fifty day moving average price is $45.33 and its 200-day moving average price is $46.13.

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes.